TY  - JOUR
AU  - Petrović, Nina
AU  - Essack, Magbubah
AU  - Šami, Ahmad
AU  - Perry, George
AU  - Gojobori, Takashi
AU  - Isenović, Esma R.
AU  - Bajić, Vladan P.
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/11351
AB  - MicroRNAs (miRNAs) are involved in the regulation of various cellular processes including pathological conditions. MiRNA networks have been extensively researched in age-related degenerative diseases, such as cancer, Alzheimer’s disease (AD), and heart failure. Thus, miRNA has been studied from different approaches, in vivo, in vitro, and in silico including miRNA networks. Networks linking diverse biomedical entities unveil information not readily observable by other means. This work focuses on biological networks related to Breast cancer susceptibility 1 (BRCA1) in AD and breast cancer (BC). Using various bioinformatics approaches, we identified subnetworks common to AD and BC that suggest they are linked. According to our results, miR-107 was identified as a potentially good candidate for both AD and BC treatment (targeting BRCA1/2 and PTEN in both diseases), accompanied by miR-146a and miR-17. The analysis also confirmed the involvement of the miR-17-92 cluster, and miR-124-3p, and highlighted the importance of poorly researched miRNAs such as mir-6785 mir6127, mir-6870, or miR-8485. After filtering the in silico analysis results, we found 49 miRNA molecules that modulate the expression of at least five genes common to both BC and AD. Those 49 miRNAs regulate the expression of 122 genes in AD and 93 genes in BC, from which 26 genes are common genes for AD and BC involved in neuron differentiation and genesis, cell differentiation and migration, regulation of cell cycle, and cancer development. Additionally, the highly enriched pathway was associated with diabetic complications, pointing out possible interplay among molecules underlying BC, AD, and diabetes pathology
T2  - Computational Biology and Chemistry
T1  - MicroRNA networks linked with BRCA1/2, PTEN, and common genes for Alzheimer's disease and breast cancer share highly enriched pathways that may unravel targets for the AD/BC comorbidity treatment
VL  - 106
SP  - 107925
DO  - 10.1016/j.compbiolchem.2023.107925
ER  - 

@article{
author = "Petrović, Nina and Essack, Magbubah and Šami, Ahmad and Perry, George and Gojobori, Takashi and Isenović, Esma R. and Bajić, Vladan P.",
year = "2023",
abstract = "MicroRNAs (miRNAs) are involved in the regulation of various cellular processes including pathological conditions. MiRNA networks have been extensively researched in age-related degenerative diseases, such as cancer, Alzheimer’s disease (AD), and heart failure. Thus, miRNA has been studied from different approaches, in vivo, in vitro, and in silico including miRNA networks. Networks linking diverse biomedical entities unveil information not readily observable by other means. This work focuses on biological networks related to Breast cancer susceptibility 1 (BRCA1) in AD and breast cancer (BC). Using various bioinformatics approaches, we identified subnetworks common to AD and BC that suggest they are linked. According to our results, miR-107 was identified as a potentially good candidate for both AD and BC treatment (targeting BRCA1/2 and PTEN in both diseases), accompanied by miR-146a and miR-17. The analysis also confirmed the involvement of the miR-17-92 cluster, and miR-124-3p, and highlighted the importance of poorly researched miRNAs such as mir-6785 mir6127, mir-6870, or miR-8485. After filtering the in silico analysis results, we found 49 miRNA molecules that modulate the expression of at least five genes common to both BC and AD. Those 49 miRNAs regulate the expression of 122 genes in AD and 93 genes in BC, from which 26 genes are common genes for AD and BC involved in neuron differentiation and genesis, cell differentiation and migration, regulation of cell cycle, and cancer development. Additionally, the highly enriched pathway was associated with diabetic complications, pointing out possible interplay among molecules underlying BC, AD, and diabetes pathology",
journal = "Computational Biology and Chemistry",
title = "MicroRNA networks linked with BRCA1/2, PTEN, and common genes for Alzheimer's disease and breast cancer share highly enriched pathways that may unravel targets for the AD/BC comorbidity treatment",
volume = "106",
pages = "107925",
doi = "10.1016/j.compbiolchem.2023.107925"
}

Petrović, N., Essack, M., Šami, A., Perry, G., Gojobori, T., Isenović, E. R.,& Bajić, V. P.. (2023). MicroRNA networks linked with BRCA1/2, PTEN, and common genes for Alzheimer's disease and breast cancer share highly enriched pathways that may unravel targets for the AD/BC comorbidity treatment. in Computational Biology and Chemistry, 106, 107925.
https://doi.org/10.1016/j.compbiolchem.2023.107925

Petrović N, Essack M, Šami A, Perry G, Gojobori T, Isenović ER, Bajić VP. MicroRNA networks linked with BRCA1/2, PTEN, and common genes for Alzheimer's disease and breast cancer share highly enriched pathways that may unravel targets for the AD/BC comorbidity treatment. in Computational Biology and Chemistry. 2023;106:107925.
doi:10.1016/j.compbiolchem.2023.107925 .

Petrović, Nina, Essack, Magbubah, Šami, Ahmad, Perry, George, Gojobori, Takashi, Isenović, Esma R., Bajić, Vladan P., "MicroRNA networks linked with BRCA1/2, PTEN, and common genes for Alzheimer's disease and breast cancer share highly enriched pathways that may unravel targets for the AD/BC comorbidity treatment" in Computational Biology and Chemistry, 106 (2023):107925,
https://doi.org/10.1016/j.compbiolchem.2023.107925 . .

TY  - JOUR
AU  - Stanimirović, Julijana
AU  - Radovanović, Jelena
AU  - Banjac, Katarina
AU  - Obradović, Milan M.
AU  - Essack, Magbubah
AU  - Zafirović, Sonja
AU  - Gluvić, Zoran
AU  - Gojobori, Takashi
AU  - Isenović, Esma R.
PY  - 2022
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10285
AB  - Even though type 2 diabetes mellitus (T2DM) represents a worldwide chronic health issue that affects about 462 million people, specific underlying determinants of insulin resistance (IR) and impaired insulin secretion are still unknown. There is growing evidence that chronic subclinical inflammation is a triggering factor in the origin of T2DM. Increased C-reactive protein (CRP) levels have been linked to excess body weight since adipocytes produce tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6), which are pivotal factors for CRP stimulation. Furthermore, it is known that hepatocytes produce relatively low rates of CRP in physiological conditions compared to T2DM patients, in which elevated levels of inflammatory markers are reported, including CRP. CRP also participates in endothelial dysfunction, the production of vasodilators, and vascular remodeling, and increased CRP level is closely associated with vascular system pathology and metabolic syndrome. In addition, insulin-based therapies may alter CRP levels in T2DM. Therefore, determining and clarifying the underlying CRP mechanism of T2DM is imperative for novel preventive and diagnostic procedures. Overall, CRP is one of the possible targets for T2DM progression and understanding the connection between insulin and inflammation may be helpful in clinical treatment and prevention approaches.
T2  - Mediators of Inflammation
T1  - Role of C-Reactive Protein in Diabetic Inflammation
VL  - 2022
SP  - e3706508
DO  - 10.1155/2022/3706508
ER  - 

@article{
author = "Stanimirović, Julijana and Radovanović, Jelena and Banjac, Katarina and Obradović, Milan M. and Essack, Magbubah and Zafirović, Sonja and Gluvić, Zoran and Gojobori, Takashi and Isenović, Esma R.",
year = "2022",
abstract = "Even though type 2 diabetes mellitus (T2DM) represents a worldwide chronic health issue that affects about 462 million people, specific underlying determinants of insulin resistance (IR) and impaired insulin secretion are still unknown. There is growing evidence that chronic subclinical inflammation is a triggering factor in the origin of T2DM. Increased C-reactive protein (CRP) levels have been linked to excess body weight since adipocytes produce tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6), which are pivotal factors for CRP stimulation. Furthermore, it is known that hepatocytes produce relatively low rates of CRP in physiological conditions compared to T2DM patients, in which elevated levels of inflammatory markers are reported, including CRP. CRP also participates in endothelial dysfunction, the production of vasodilators, and vascular remodeling, and increased CRP level is closely associated with vascular system pathology and metabolic syndrome. In addition, insulin-based therapies may alter CRP levels in T2DM. Therefore, determining and clarifying the underlying CRP mechanism of T2DM is imperative for novel preventive and diagnostic procedures. Overall, CRP is one of the possible targets for T2DM progression and understanding the connection between insulin and inflammation may be helpful in clinical treatment and prevention approaches.",
journal = "Mediators of Inflammation",
title = "Role of C-Reactive Protein in Diabetic Inflammation",
volume = "2022",
pages = "e3706508",
doi = "10.1155/2022/3706508"
}

Stanimirović, J., Radovanović, J., Banjac, K., Obradović, M. M., Essack, M., Zafirović, S., Gluvić, Z., Gojobori, T.,& Isenović, E. R.. (2022). Role of C-Reactive Protein in Diabetic Inflammation. in Mediators of Inflammation, 2022, e3706508.
https://doi.org/10.1155/2022/3706508

Stanimirović J, Radovanović J, Banjac K, Obradović MM, Essack M, Zafirović S, Gluvić Z, Gojobori T, Isenović ER. Role of C-Reactive Protein in Diabetic Inflammation. in Mediators of Inflammation. 2022;2022:e3706508.
doi:10.1155/2022/3706508 .

Stanimirović, Julijana, Radovanović, Jelena, Banjac, Katarina, Obradović, Milan M., Essack, Magbubah, Zafirović, Sonja, Gluvić, Zoran, Gojobori, Takashi, Isenović, Esma R., "Role of C-Reactive Protein in Diabetic Inflammation" in Mediators of Inflammation, 2022 (2022):e3706508,
https://doi.org/10.1155/2022/3706508 . .

TY  - JOUR
AU  - Gluvić, Zoran
AU  - Obradović, Milan M.
AU  - Stewart, Alan J.
AU  - Essack, Magbubah
AU  - Pitt, Samantha J.
AU  - Samardžić, Vladimir
AU  - Soskić, Sanja S.
AU  - Gojobori, Takashi
AU  - Isenović, Esma R.
PY  - 2021
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10047
AB  - Levothyroxine (LT4) is used to treat frequently encountered endocrinopathies such as thyroid diseases. It is regularly used in clinical (overt) hypothyroidism cases and subclinical (latent) hypothyroidism cases in the last decade. Suppressive LT4 therapy is also part of the medical regimen used to manage thyroid malignancies after a thyroidectomy. LT4 treatment possesses dual effects: substituting new-onset thyroid hormone deficiency and suppressing the local and distant malignancy spreading in cancer. It is the practice to administer LT4 in less-than-high suppressive doses for growth control of thyroid nodules and goiter, even in patients with preserved thyroid function. Despite its approved safety for clinical use, LT4 can sometimes induce side-effects, more often recorded with patients under treatment with LT4 suppressive doses than in unintentionally LT4-overdosed patients. Cardiac arrhythmias and the deterioration of osteoporosis are the most frequently documented side-effects of LT4 therapy. It also lowers the threshold for the onset or aggravation of cardiac arrhythmias for patients with pre-existing heart diseases. To improve the quality of life in LT4-substituted patients, clinicians often prescribe higher doses of LT4 to reach low normal TSH levels to achieve cellular euthyroidism. In such circumstances, the risk of cardiac arrhythmias, particularly atrial fibrillation, increases, and the combined use of LT4 and triiodothyronine further complicates such risk. This review summarizes the relevant available data related to LT4 suppressive treatment and the associated risk of cardiac arrhythmia.
T2  - Frontiers in Endocrinology
T1  - Levothyroxine Treatment and the Risk of Cardiac Arrhythmias – Focus on the Patient Submitted to Thyroid Surgery
VL  - 12
SP  - 1415
DO  - 10.3389/fendo.2021.758043
ER  - 

@article{
author = "Gluvić, Zoran and Obradović, Milan M. and Stewart, Alan J. and Essack, Magbubah and Pitt, Samantha J. and Samardžić, Vladimir and Soskić, Sanja S. and Gojobori, Takashi and Isenović, Esma R.",
year = "2021",
abstract = "Levothyroxine (LT4) is used to treat frequently encountered endocrinopathies such as thyroid diseases. It is regularly used in clinical (overt) hypothyroidism cases and subclinical (latent) hypothyroidism cases in the last decade. Suppressive LT4 therapy is also part of the medical regimen used to manage thyroid malignancies after a thyroidectomy. LT4 treatment possesses dual effects: substituting new-onset thyroid hormone deficiency and suppressing the local and distant malignancy spreading in cancer. It is the practice to administer LT4 in less-than-high suppressive doses for growth control of thyroid nodules and goiter, even in patients with preserved thyroid function. Despite its approved safety for clinical use, LT4 can sometimes induce side-effects, more often recorded with patients under treatment with LT4 suppressive doses than in unintentionally LT4-overdosed patients. Cardiac arrhythmias and the deterioration of osteoporosis are the most frequently documented side-effects of LT4 therapy. It also lowers the threshold for the onset or aggravation of cardiac arrhythmias for patients with pre-existing heart diseases. To improve the quality of life in LT4-substituted patients, clinicians often prescribe higher doses of LT4 to reach low normal TSH levels to achieve cellular euthyroidism. In such circumstances, the risk of cardiac arrhythmias, particularly atrial fibrillation, increases, and the combined use of LT4 and triiodothyronine further complicates such risk. This review summarizes the relevant available data related to LT4 suppressive treatment and the associated risk of cardiac arrhythmia.",
journal = "Frontiers in Endocrinology",
title = "Levothyroxine Treatment and the Risk of Cardiac Arrhythmias – Focus on the Patient Submitted to Thyroid Surgery",
volume = "12",
pages = "1415",
doi = "10.3389/fendo.2021.758043"
}

Gluvić, Z., Obradović, M. M., Stewart, A. J., Essack, M., Pitt, S. J., Samardžić, V., Soskić, S. S., Gojobori, T.,& Isenović, E. R.. (2021). Levothyroxine Treatment and the Risk of Cardiac Arrhythmias – Focus on the Patient Submitted to Thyroid Surgery. in Frontiers in Endocrinology, 12, 1415.
https://doi.org/10.3389/fendo.2021.758043

Gluvić Z, Obradović MM, Stewart AJ, Essack M, Pitt SJ, Samardžić V, Soskić SS, Gojobori T, Isenović ER. Levothyroxine Treatment and the Risk of Cardiac Arrhythmias – Focus on the Patient Submitted to Thyroid Surgery. in Frontiers in Endocrinology. 2021;12:1415.
doi:10.3389/fendo.2021.758043 .

Gluvić, Zoran, Obradović, Milan M., Stewart, Alan J., Essack, Magbubah, Pitt, Samantha J., Samardžić, Vladimir, Soskić, Sanja S., Gojobori, Takashi, Isenović, Esma R., "Levothyroxine Treatment and the Risk of Cardiac Arrhythmias – Focus on the Patient Submitted to Thyroid Surgery" in Frontiers in Endocrinology, 12 (2021):1415,
https://doi.org/10.3389/fendo.2021.758043 . .

TY  - JOUR
AU  - Obradović, Milan
AU  - Sudar-Milovanović, Emina
AU  - Soskić, Sanja S.
AU  - Essack, Magbubah
AU  - Arya, Swati
AU  - Stewart, Alan J.
AU  - Gojobori, Takashi
AU  - Isenović, Esma R.
PY  - 2021
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/9833
AB  - The peptide hormone leptin regulates food intake, body mass, and reproductive function and plays a role in fetal growth, proinflammatory immune responses, angiogenesis and lipolysis. Leptin is a product of the obese (ob) gene and, following synthesis and secretion from fat cells in white adipose tissue, binds to and activates its cognate receptor, the leptin receptor (LEP-R). LEP-R distribution facilitates leptin’s pleiotropic effects, playing a crucial role in regulating body mass via a negative feedback mechanism between adipose tissue and the hypothalamus. Leptin resistance is characterized by reduced satiety, over-consumption of nutrients, and increased total body mass. Often this leads to obesity, which reduces the effectiveness of using exogenous leptin as a therapeutic agent. Thus, combining leptin therapies with leptin sensitizers may help overcome such resistance and, consequently, obesity. This review examines recent data obtained from human and animal studies related to leptin, its role in obesity, and its usefulness in obesity treatment.
T2  - Frontiers in Endocrinology
T1  - Leptin and Obesity: Role and Clinical Implication
VL  - 12
SP  - 563
DO  - 10.3389/fendo.2021.585887
ER  - 

@article{
author = "Obradović, Milan and Sudar-Milovanović, Emina and Soskić, Sanja S. and Essack, Magbubah and Arya, Swati and Stewart, Alan J. and Gojobori, Takashi and Isenović, Esma R.",
year = "2021",
abstract = "The peptide hormone leptin regulates food intake, body mass, and reproductive function and plays a role in fetal growth, proinflammatory immune responses, angiogenesis and lipolysis. Leptin is a product of the obese (ob) gene and, following synthesis and secretion from fat cells in white adipose tissue, binds to and activates its cognate receptor, the leptin receptor (LEP-R). LEP-R distribution facilitates leptin’s pleiotropic effects, playing a crucial role in regulating body mass via a negative feedback mechanism between adipose tissue and the hypothalamus. Leptin resistance is characterized by reduced satiety, over-consumption of nutrients, and increased total body mass. Often this leads to obesity, which reduces the effectiveness of using exogenous leptin as a therapeutic agent. Thus, combining leptin therapies with leptin sensitizers may help overcome such resistance and, consequently, obesity. This review examines recent data obtained from human and animal studies related to leptin, its role in obesity, and its usefulness in obesity treatment.",
journal = "Frontiers in Endocrinology",
title = "Leptin and Obesity: Role and Clinical Implication",
volume = "12",
pages = "563",
doi = "10.3389/fendo.2021.585887"
}

Obradović, M., Sudar-Milovanović, E., Soskić, S. S., Essack, M., Arya, S., Stewart, A. J., Gojobori, T.,& Isenović, E. R.. (2021). Leptin and Obesity: Role and Clinical Implication. in Frontiers in Endocrinology, 12, 563.
https://doi.org/10.3389/fendo.2021.585887

Obradović M, Sudar-Milovanović E, Soskić SS, Essack M, Arya S, Stewart AJ, Gojobori T, Isenović ER. Leptin and Obesity: Role and Clinical Implication. in Frontiers in Endocrinology. 2021;12:563.
doi:10.3389/fendo.2021.585887 .

Obradović, Milan, Sudar-Milovanović, Emina, Soskić, Sanja S., Essack, Magbubah, Arya, Swati, Stewart, Alan J., Gojobori, Takashi, Isenović, Esma R., "Leptin and Obesity: Role and Clinical Implication" in Frontiers in Endocrinology, 12 (2021):563,
https://doi.org/10.3389/fendo.2021.585887 . .